Article
Recent Developments On Patent-Eligibility Of Medical Use Claims In Canada
Last December, the Federal Court of Canada overturned a decision of the Commissioner of Patents to refuse a patent claiming a fixed dosage regimen for the drug Humira® (Adalimunab) used in rheumatoid arthritis.
Goudreau Gage Dubuc
